Flora Peyvandi

35.9k total citations · 7 hit papers
652 papers, 18.3k citations indexed

About

Flora Peyvandi is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Flora Peyvandi has authored 652 papers receiving a total of 18.3k indexed citations (citations by other indexed papers that have themselves been cited), including 457 papers in Hematology, 148 papers in Genetics and 122 papers in Immunology. Recurrent topics in Flora Peyvandi's work include Hemophilia Treatment and Research (263 papers), Platelet Disorders and Treatments (224 papers) and Blood Coagulation and Thrombosis Mechanisms (166 papers). Flora Peyvandi is often cited by papers focused on Hemophilia Treatment and Research (263 papers), Platelet Disorders and Treatments (224 papers) and Blood Coagulation and Thrombosis Mechanisms (166 papers). Flora Peyvandi collaborates with scholars based in Italy, United States and United Kingdom. Flora Peyvandi's co-authors include Pier Mannuccio Mannucci, Roberta Palla, Stefano Duga, Marzia Menegatti, Marie Scully, Isabella Garagiola, Armando Tripodi, Isabella Garagiola, Veena Chantarangkul and Rosanna Asselta and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Flora Peyvandi

608 papers receiving 17.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

2020 935 citations Flora Peyvandi, Armando Tripodi et al. profile →
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

2019 602 citations Marie Scully, Spero R. Cataland et al. profile →
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

2012 553 citations Marie Scully, Flora Peyvandi et al. profile →
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

2016 429 citations Flora Peyvandi, Marie Scully et al. profile →
The past and future of haemophilia: diagnosis, treatments, and its complications

2016 321 citations Flora Peyvandi et al. profile →
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

2022 163 citations Flora Peyvandi et al. profile →
Hemophilic arthropathy: Current knowledge and future perspectives

2021 150 citations Roberta Gualtierotti, Flora Peyvandi et al. profile →

Peers

Countries citing papers authored by Flora Peyvandi

Since Specialization

Citations

This map shows the geographic impact of Flora Peyvandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flora Peyvandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flora Peyvandi more than expected).

Fields of papers citing papers by Flora Peyvandi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flora Peyvandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flora Peyvandi. The network helps show where Flora Peyvandi may publish in the future.

Co-authorship network of co-authors of Flora Peyvandi

This figure shows the co-authorship network connecting the top 25 collaborators of Flora Peyvandi. A scholar is included among the top collaborators of Flora Peyvandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flora Peyvandi. Flora Peyvandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study 2024 ·European Journal Of Haematology ·Paola Giordano, (unknown), Gianluca Sottilotta, Chiara Biasoli, (unknown), Raimondo De Cristofaro, Flora Peyvandi, (unknown), Giancarlo Castaman, (unknown)	1
2	D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation 2024 ·Blood Advances ·Armando Tripodi, Marco Capecchi, Erica Scalambrino, Marigrazia Clerici, (unknown), Pasquale Agosti, Paolo Bucciarelli, Flora Peyvandi	2
3	Rare bleeding disorders: Advances in management 2024 ·Haemophilia ·Alessandro Casini, Hanny Al‐Samkari, Catherine P.M. Hayward, Flora Peyvandi	4
4	Comparative Investigation of Thromboelastometry and Thrombin Generation for Patients Receiving Direct Oral Anticoagulants or Vitamin K Antagonists 2024 ·Diagnostics ·Armando Tripodi, Marco Capecchi, Erica Scalambrino, Marigrazia Clerici, (unknown), Pasquale Agosti, Paolo Bucciarelli, Andrea Artoni, Flora Peyvandi	1
5	Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients 2023 ·Journal of Clinical Medicine ·Roberta Gualtierotti, Sharon Fox, (unknown), (unknown), Luca Valenti, María Orietta Borghi, Pier Luigi Meroni, Massimo Cugno, Flora Peyvandi, (unknown)	3
6	Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study 2023 ·Blood ·Lynn Malec, An Van Damme, Anthony K.C. Chan, Mariya Spasova, Nisha Jain, (unknown), Jennifer Dumont, Stefan Lethagen, Manuel Carção, Flora Peyvandi	9
7	Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. 2023 ·PubMed Central ·Samantha Pasca, Ezio Zanon, Pier Mannuccio Mannucci, Flora Peyvandi	16
8	Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices 2023 ·Haemophilia ·Ilaria Cutica, (unknown), Isabella Garagiola, Gabriella Pravettoni, Flora Peyvandi	1
9	Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2 2022 ·Blood Advances ·(unknown), Luciano Baronciani, M Pagliari, Giovanna Cozzi, (unknown), (unknown), Simona Maria Siboni, Eugenia Biguzzi, Flora Peyvandi	17
10	Lung Ultrasound Findings and Endothelial Perturbation in a COVID-19 Low-Intensity Care Unit 2022 ·Journal of Clinical Medicine ·Roberta Gualtierotti, (unknown), Paolo Rossi, Matteo Rota, Paolo Bucciarelli, Barbara Ferrari, (unknown), Chiara Suffritti, Massimo Cugno, Flora Peyvandi, (unknown)	3
11	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia 2022 ·Cells ·Vincenzo La Mura, Nicoletta Gagliano, Francesca Arnaboldi, Patrizia Sartori, P. Procacci, (unknown), Eleonora Liguori, (unknown), Giuseppe Ristagno, Roberto Latini, Daniele Dondossola, Francesco Salerno, Armando Tripodi, Massimo Colombo, Flora Peyvandi	13
12	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis 2021 ·Blood Advances ·Flora Peyvandi, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, (unknown), Hilde De Winter, Filip Callewaert	50
13	Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis 2019 ·Blood Advances ·Angela C. Weyand, (unknown), (unknown), (unknown), (unknown), Marzia Menegatti, Catherine E. Richter, Rosanna Asselta, Stefano Duga, Flora Peyvandi, Jordan A. Shavit	21
14	First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries 2018 ·Haemophilia ·Glenn F. Pierce, (unknown), (unknown), Flora Peyvandi, Saliou Diop, Magdy El Ekiaby, H. Marijke van den Berg	29
15	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls 2018 ·Haemophilia ·Pier Mannuccio Mannucci, Alessandro Nobili, Emanuela Marchesini, (unknown), Laura Cortesi, Antonio Coppola, Elena Santagostino, Paolo Radossi, Giancarlo Castaman, Lelia Valdré, Cristina Santoro, Annarita Tagliaferri, (unknown), Ezio Zanon, Giovanni Barillari, (unknown), Teresa Maria Caimi, Gianluca Sottilotta, Flora Peyvandi, Alfonso Iorio	6
16	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis 2017 ·Blood ·Frits R. Rosendaal, Roberta Palla, Isabella Garagiola, Pier Mannuccio Mannucci, Flora Peyvandi	28
17	Eahad-DB: a combined coagulation factor variant databases resource for the clinical and scientificcommunities 2015 ·View ·(unknown), Athena H. Cairo, Brian Dolan, Muriel Giansily‐Blaizot, Keith Gomez, Anne Goodeve, Geoffrey Kemball‐Cook, (unknown), John H. McVey, Johannes Oldenburg, Sarah E. Perkins, Flora Peyvandi, (unknown)	1
18	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency 2013 ·PEDIATRICS ·Ida Martinelli, Paolo Bucciarelli, Andrea Artoni, Emilio Fossali, Serena M. Passamonti, Armando Tripodi, Flora Peyvandi	29
19	Discrepancies between different types of ADAMTS13 assays in patients with thrombotic microangiopathies 2011 ·UCL Discovery (University College London) ·IJ Mackie, (unknown), A Chitolie, (unknown), (unknown), SJ Machin, Flora Peyvandi	0
20	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). 2003 ·PubMed ·Pier Mannuccio Mannucci, Mehran Karimi, Ahmad Mosalaei, Maria Teresa Canciani, Flora Peyvandi	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact